| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | See Remarks
5 companies
Jerome B Zeldis is Director at STEX, with reported holdings spanning 5 companies. From April 2015 to January 2026, the filings on record show 12 open-market purchases and 3 sales. Jerome B Zeldis's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.1M at current prices.
Our model assigns Jerome B Zeldis a below-average insider score of 45/100, based on 8 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -18.0%.
Jerome B Zeldis's largest disclosed position is in PTCT, worth about $1.5M. The PTCT filings lean toward selling, a net 44,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2019 | SNGX Soligenix, Inc. | Director | Buy | 2,000 | $0.93 | $1,850.00 | +9.6% | |
| Sep 19, 2019 | SNGX Soligenix, Inc. | Director | Buy | 4,000 | $0.94 | $3,740.00 | +23.6% | |
| Apr 22, 2019 | SNGX Soligenix, Inc. | Director | Buy | 10,000 | $0.73 | $7,274.00 | +144.6% | |
| Feb 3, 2017 | SRNE Sorrento Therapeutics, Inc. | See Remarks | Buy | 10,000 | $5.15 | $51,500.00 | New | |
| Dec 23, 2015 | SNGX Soligenix, Inc. | Director | Buy | 2,500 | $1.27 | $3,175.00 | +3.8% |